WHO issues new guidelines for malaria treatment
The World Health Organisation has asked pharmaceutical companies to end the marketing and sale of "single-drug" artemisinin malaria medicines, in order to prevent malaria parasites from developing resistance to the drug.
bdnews24.com News Service
bdnews24.com
Published :
20 Jan 2006, 06:00 PM
Updated :
17 Aug 2022, 05:42 PM
Washington, Jan 21 (BDNEWS) - The World Health Organisation has asked pharmaceutical companies to end the marketing and sale of "single-drug" artemisinin malaria medicines, in order to prevent malaria parasites from developing resistance to the drug.
The use of single-drug artemisinin treatment, or "monotherapy", hastens development of resistance by weakening but not killing the parasite, WHO said in new malaria treatment guidelines.
"We request pharmaceutical companies to immediately stop marketing single-drug artemisinin tablets and instead market artem-isinin combination therapies only," WHO Director-General Dr Lee Jong-wook said in a statement.
"It is critical that artem-isinins be used correctly." When used correctly in combination with other anti-malarial drugs in Artem-isinin Combination Therapies, artemisinin is nearly 95 per cent effective in curing malaria and the parasite is highly unlikely to become drug-resistant, the United Nations health agency said.
Malaria, caused by a one-celled parasite carried by mosquitoes called plasmodium, kills at least a million people every year and makes 300 million people seriously ill.
According to WHO's new treatment guidelines, Falciparum malaria must be treated with Artemisinin Combination Therapies (ACTs) and not by artemisinin alone or any other monotherapy.
WHO urged malaria researchers and the pharmaceutical industry to quickly invest in development of the next generation of antimalarial drugs. "Our biggest concern right now is to treat patients with safe and effective medication and to avoid the emergence of drug resistance. If we lose ACTs, we'll no longer have a cure for malaria," Malaria department director Dr Atara Kochi said.
BDNEWS/1707 hrs